Design of experiments as a tool for LC-MS/MS method development for the trace analysis of the potentially genotoxic 4-dimethylaminopyridine impurity in glucocorticoids

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 251-258

  Székely, Gy ^a,b   Henriques, B ^a   Gil, M ^a   Ramos, A ^a   Alvarez, C ^a  

^a Hovione FarmaCiencia SA   (Portugal)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

4 Dimethylaminopyridine; Design of experiments; Glucocorticoids; LC MS MS; Potentially genotoxic impurity

Indexed keywords

4 DIMETHYLAMINOPYRIDINE; BECLOMETASONE DIPROPIONATE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HOLOBETASOLE PROPIONATE; MOMETASONE FUROATE; TRACE ELEMENT; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CENTRAL COMPOSITE FACE; COLLISION ENERGY; CONE VOLTAGE; CONTROLLED STUDY; DESIGN OF EXPERIMENT; DRUG IMPURITY; DRUG INJECTION VOLUME; ERROR; GENOTOXICITY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATHEMATICAL MODEL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; STATISTICAL MODEL; STUDY DESIGN; VALIDATION STUDY;

4-AMINOPYRIDINE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; GLUCOCORTICOIDS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MUTAGENS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SIGNAL-TO-NOISE RATIO; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84866240030     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.07.006     Document Type: Article

References (29)

1. Guidance for industry, Genotoxic and carcinogenic impurities in drug substances and products: recommended approaches, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), December 2008.
2. Liu D.Q., Sun M., Kord A.S. Recent advances in trace analysis of pharmaceutical genotoxic impurities. J. Pharm. Biomed. Anal. 2010, 51:999-1014.
3. Székely Gy., Bandarra J., Heggie W., Sellergren B., Ferreira F.C. Organic solvent nanofiltration: a platform for removal of genotoxins from active pharmaceutical ingredients. J. Membr. Sci. 2011, 381:21-33.
4. Sun M., Liu D.Q., Kord A.S. A systematic method development strategy for determination of pharmaceutical genotoxic impurities. Org. Process Res. Dev. 2010, 14:977-985.
5. Vanhoenacker G., Dumont E., David F., Baker A., Sandra P. Determination of arylamines and aminopyridines in pharmaceutical products using in situ derivatization and liquid chromatography-mass spectrometry. J. Chromatogr. A 2009, 1216:3563-3570.
6. van Wijk A.M., Beerman B., Niederländer H.A.G., Siebum A.H.G., de Jong G.J. A new approach for generic screening and quantitation of potential genotoxic alkylation compounds by pre-column derivatization and LC-MS/MS analysis. Anal. Bioanal. Chem. 2011, 400:1375-1385.
7. Teasdale A. Genotoxic Impurities-Strategies for Identification and Control 2010, John Wiley and Sons Inc., New Jersey.
8. Bousquet J. Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. Int. J. Clin. Pract. 2009, 63:806-819.
9. Foley K.M., Abernath A. Management of Cancer Pain in Cancer: Principles and Practice of Oncology 2008, 2757-2790. Lippincott Williams and Wilkins, Philadelphia. DeVita, Hellman, Rosenberg (Eds.).
10. Kris M.G. American society of clinical oncology guideline for antiemetics in oncology. J. Clin. Oncol. 2006, 24:2932-2947.
11. Draper R.W., McPhail A.T., Puar M.S., Vater E.J., Weber L. Unusual hydroxy-(-sultone byproducts of steroid 21-methanesulfonylation: an efficient synthesis of mometasone 17-furoate (Sch 32088). Tetrahedron 1999, 55:3355-3364.
12. J. Elks, G.H., Phillipps, Ger. Offen., 1,902,340 via Chem. Abstr. (1970).
13. Müller L., Mauthe R.J., Riley C.M., Andino M.M., Antonis D., Beels C., DeGeorge J., Knaep A.G.M., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D.N., Jacks A.S., Jagota N. A rationale for determining testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharm. 2006, 44:198-211.
14. EMA/CHMP/SWP/431994/2007 Rev. 3, 23 September 2010.
15. Huang L., Yub D., Hoa P., Leeb K., Chen C., Synthesis anti-HIV activity of bi-functional triterpene derivatives. Lett. Drug Des. Discov. 2007, 4:471-478.
16. Venkateswara B., Ramanjaneyulu K., Bhaskara T. Synthesis and bioactivity evaluation of cinnamic acid esters from oxalis pescaprace. J. Chem. Pharm. Res. 2011, 3:589-594.
17. A.R. Stamvik, S.K., Kristensson, K. Lundvall, Steroid Esters Preparation, US Patent 4,537,722, assigned to Ab Leo, Helsingborg, Sweden (1985).
18. Zutter U., Iding H., Spurr P., Wirz B. New efficient synthesis of oseltamivir phosphate (Tamiflu) via enzymatic desymmetrization of a meso-1,3-cyclohexanedicarboxylic acid diester. J. Org. Chem. 2008, 73:4895-4902.
19. Yeung Y.Y., Hong S., Corey E.J. A short enantioselective pathway for the synthesis of the anti-influenza neuramidase inhibitor oseltamivir from 1,3-butadiene and acrylic acid. J. Am. Chem. Soc. 2006, 128:6310-6311.
20. Gentric L., Hanna I., Ricard L. Synthesis of the complete carbocyclic skeleton of Vinigrol. Org. Lett. 2003, 5:1139-1142.
21. Coleman R.E. Glucocorticoids in cancer therapy. Biotherapy 1992, 4:37-44.
22. Dermatologic Disease Database, http://www.aocd.org/skin/dermatologic_diseases/steroids.html.
23. EMEA guidelines Limits for Genotoxic Impurities EMEA/CHMP/QWP/251334/2006.
24. Giordani A., Kobel W., Gally H.U. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process. Eur. J. Pharm. Sci. 2011, 43:1-15.
25. Furlanetto S., Orlandini S., Giannini I., Beretta G., Pinzauti S. Pitfalls and success of experimental design in the development of a mixed MEKC method for the analysis of budesonide and its impurities. Electrophoresis 2009, 30:633-643.
26. Vogt F.G., Kord A.S. Development of quality-by-design analytical methods. J. Pharm. Sci. 2011, 100:797-812.
27. Fekete S., Fekete J., Molnár I., Ganzler K. Rapid high performance liquid chromatography method development with high prediction accuracy, using 5cm long narrow bore columns packed with sub-2μm particles and design space computer modeling. J. Chromatogr. A 2009, 1216:7816-7823.
28. Hop C.E.C.A., Dakubu M., Holmes J.L. Do the aminopyrisdine molecular ions display aniline- or pyridine-type behaviour?. Org. Mass Spectrom. 1988, 23:609-612.
29. Eriksson L., Johansson E., Kettaneh-Wold N., Wikström C., Wold S. Design of Experiments-Principles and Applications 2008, Umetrics Academy Publisher, ISBN 10-91-973730-4-4.